Tirzepatide outperforms semaglutide in clinical trial with faster weight loss
A major trial shows tirzepatide, recently launched in India, helps people lose more weight and shrink their waistlines faster than semaglutide.A new study has found that tirzepatide, a weight-loss injection introduced in India this March, is more effective than semaglutide, a popular obesity drug already available in the country.In a clinical trial that ran for 72 weeks, people who took tirzepatide lost about 23 kg on average, while those on semaglutide lost around 15 kg.advertisement
Both drugs were given once a week through injections, and participants also followed a controlled diet and exercised regularly.The research, published in The New England Journal of Medicine, showed that tirzepatide also helped people reduce more belly fat, with an average waistline drop of 7.2 inches, compared to 5.1 inches with semaglutide.Tirzepatide is sold under the brand name Mounjaro, developed by US-based company Eli Lilly. It's a dual-action drug (dual GIP and GLP-1 receptor agonist), which means it targets two hormones that control appetite and blood sugar. This helps people feel full sooner and eat less.
Tirzepatide is sold under the brand name Mounjaro, developed by US-based company Eli Lilly. ()
advertisementSemaglutide, made by Danish drugmaker Novo Nordisk, works in a similar way but acts on just one hormone (mono GLP-1 receptor agonist). A lower-dose pill version of semaglutide (Rybelsus) has been available in India since 2022, but the more powerful injectables (Ozempic and Wegovy) have not yet launched here.Novo Nordisk has confirmed it plans to bring Wegovy to India later this year.In the study, 65% of people who took tirzepatide lost at least 15% of their body weight, compared to 40% of those on semaglutide.'It's a big step forward in treating obesity, which is a serious long-term health condition,' said Winselow Tucker, President and General Manager of Lilly India.The trial involved 751 participants from the US and Puerto Rico, all of whom were either obese (BMI over 30) or overweight (BMI 25–30) with other health issues like high blood pressure, sleep apnea, or heart disease, but none had diabetes. Everyone was given diet and exercise advice, in addition to the weekly injection.SIDE EFFECTS AND SAFETYLike many weight-loss drugs, both tirzepatide and semaglutide caused mild to moderate side effects, mainly stomach-related issues like nausea, vomiting, and bloating.A small number of people stopped taking the drugs because of side effects, about 6% on tirzepatide and 8% on semaglutide.advertisementThe researchers noted that while the trial wasn't designed to directly compare the safety of both drugs, the findings were consistent with earlier studies.Both tirzepatide and semaglutide are prescription-only and should only be taken under a doctor's supervision. They are not meant for short-term or cosmetic use, and regular monitoring is required to manage side effects. You May Also Like
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 hours ago
- The Hindu
Advent to invest $175 million in Felix Pharma to acquire minority stake
Advent, a private equity investor, has announced that funds managed by it have signed a definitive agreement to invest $175 million via primary and secondary capital for a significant minority stake in Dublin, Ireland-based Felix Pharmaceuticals Pvt. Ltd. (Felix), a global Gx animal pharma player. Felix Pharma is one of the developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the U.S. Shweta Jalan, Managing Partner, Advent, said, 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx. Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities.' 'Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' she added, Founded in 2015 by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, Chair of GSK and with 30 years of experience in global pharmaceuticals, and Dr. Shumeet Banerji, ex-CEO of Booz-Allen, Felix said it has pursued strategic growth through a disciplined approach, While the company achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline. It has a USFDA-approved oral solid facility dedicated to animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder, Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger. Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence.'
Indian Express
3 hours ago
- Indian Express
Ahmedabad reports highest single-day rise in Covid cases; state's active case tally at 1,109
With 131 new cases of Covid in Ahmedabad — the highest single-day rise in the city — the state recorded 235 new cases on Monday. Ahmedabad Municipal Corporation's (AMC's) health officials confirmed that Monday's was the highest number of Covid cases that the city has reported in 24 hours after the fresh spate of cases. The total number of active cases in the state stands at 1,109, including 33 people who needed hospitalisation. Others are undergoing OPD-based treatment. Another 106 people, who recovered from the virus, were discharged on Monday. As per a health bulletin released by the state government, no death was reported in Gujarat on Monday. In Ahmedabad, the tally of cases has gone up to 916, including 646 active. Ahmedabad city has reported two deaths due to Covid. Among the active cases in Ahmedabad, highest were reported in the the west zone at 211, followed by the north west zone at 204, and south west zone at 114. The remaining zones have reported 50 (south zone), 25 (north zone), 24 (east zone), 18 (central zone) cases. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), the XFG variant of the Covid-19 has been recently found in a total of 163 samples — with the highest (89) in Maharashtra, followed by Tamil Nadu (16), Kerala (15), Gujarat (11), and Andhra Pradesh, Madhya Pradesh and West Bengal (6 each). The recombinant XFG variant harbours four key spike mutations and has achieved rapid global spread following its initial detection in Canada, according to an article in The Lancet journal. In May, as many as 159 samples were detected with XFG variant, two in April, and two in June yet, data shows. India's active Covid case tally crossed the 6,000 mark, with 769 having been added to it in 48 hours, according to Union Health Ministry data released on Sunday
Time of India
5 hours ago
- Time of India
Luxury skincare expansion: L'Oreal acquires majority stake in Medik8; announces 1 billion Euro deal
Cosmetics maker L'Oreal agreed to acquire a majority stake in British skincare brand Medik8, in a strategic move to strengthen its presence in the booming skincare market. The French beauty giant announced the deal on Monday, though financial terms were not disclosed. The transaction, which sees UK-based private equity firm Inflexion selling its majority holding, reportedly values Medik8 at around 1 billion Euro, according to a source familiar with the matter. Inflexion will retain a minority share, while L'Oreal has secured the option to eventually buy out all remaining shareholders, Reuters reported. 'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' Cyril Chaupuy, president of L'oreal Luxe said. 'This acquisition further strengthens L'Oreal's luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth,' the company said in a statement. L'Oreal will begin consolidating Medik8's sales once the transaction officially closes. The acquisition is expected to be finalised in the coming months, pending regulatory approvals and standard closing conditions. Simon Coble, CEO of Medik8 also expressed excitement on the brand's behalf. 'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.' Founded in the UK, Medik8 has built a loyal customer base with its vitamin A-focused anti-ageing creams and serums. The brand is seen as a natural fit for L'Oreal's luxury division, which includes skincare and fragrance names such as Lancome, Aesop, and Miu Miu. Last year, sales in L'Oreal's luxe segment grew by just 2.7%, its weakest performance across divisions, as inflation pushed consumers toward more affordable alternatives. However, the unit scrored better than rival LVMH's beauty arm. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
